Cimzia

Approved Uses

Cimzia is used in adults to manage symptoms and reduce the progression of various inflammatory diseases. It is typically prescribed for the following conditions:

• Crohn's Disease: It is used to reduce signs and symptoms and maintain clinical response in adults with moderate to severe Crohn's disease who have not responded well to conventional treatments.
• Rheumatoid Arthritis: It is used to treat moderate to severe active rheumatoid arthritis.
• Psoriatic Arthritis: It is used to treat adults with active psoriatic arthritis.
• Ankylosing Spondylitis: It is used to treat adults with active ankylosing spondylitis.
• Non-radiographic Axial Spondyloarthritis: It is used for adults with active axial spondyloarthritis who show objective signs of inflammation but do not have X-ray evidence of the disease.
• Plaque Psoriasis: It is used for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy (light treatment).

Targeting TNF-Alpha

Cimzia belongs to a class of drugs called tumor necrosis factor (TNF) blockers. TNF is a protein produced by the immune system that plays a key role in causing inflammation. In people with certain autoimmune diseases, the body produces too much TNF, which leads to pain, swelling, and damage to healthy tissues.

Neutralizing Inflammation

The medication works by binding directly to TNF-alpha proteins in the body. By attaching to these proteins, Cimzia prevents them from interacting with cell receptors that trigger the inflammatory response. This process helps to calm the overactive immune system and reduce the symptoms associated with conditions like rheumatoid arthritis, Crohn's disease, and plaque psoriasis.

Extended Action

Cimzia is a pegylated antibody fragment. This means it has been chemically modified with polyethylene glycol (PEG), which allows the medication to remain active in the bloodstream for a longer duration. This design helps maintain a consistent level of the drug in the body to provide ongoing relief from inflammation.

Common Side Effects

The most frequently reported side effects of Cimzia include:

• Upper respiratory infections, such as the common cold or sinus infections
• Urinary tract infections
• Skin rash
• Injection site reactions, including redness, itching, pain, or swelling where the medicine was injected

Serious Side Effects

While less common, Cimzia can cause serious side effects that require immediate medical attention. These may include:

• Serious infections: Because Cimzia affects the immune system, it can increase the risk of severe bacterial, fungal, or viral infections, including tuberculosis.
• Heart failure: New or worsening symptoms of heart failure, such as shortness of breath or swelling of the ankles and feet.
• Nervous system problems: Symptoms such as dizziness, numbness or tingling, vision changes, or weakness in the arms or legs.
• Liver problems: Signs include yellowing of the skin or eyes (jaundice), dark urine, or pain on the right side of the stomach area.
• Blood disorders: Low blood cell counts, which may cause fever, bruising, or bleeding easily.
• Allergic reactions: Severe reactions including hives, swelling of the face or throat, and difficulty breathing.
• Lupus-like syndrome: Symptoms such as joint pain or a rash on the cheeks or arms that worsens in the sun.

Serious Infections

Cimzia increases the risk of developing serious infections that may lead to hospitalization or death. These include tuberculosis (TB), bacterial sepsis, and invasive fungal infections such as histoplasmosis. Healthcare providers typically test for TB before starting treatment and monitor for signs of infection during therapy.

Malignancy

Lymphoma and other cancers, some fatal, have been reported in patients using TNF blockers like Cimzia. Cases of hepatosplenic T-cell lymphoma have occurred primarily in adolescents and young adults with inflammatory bowel disease treated with TNF blockers in combination with other medications.

Neurological and Hematological Effects

TNF blockers have been associated with rare cases of new-onset or worsening central nervous system demyelinating diseases, such as multiple sclerosis. Additionally, rare but serious blood disorders, including low blood cell counts (pancytopenia), have been reported.

Heart Failure and Autoimmunity

Cimzia may worsen existing congestive heart failure or cause new heart failure. Some patients may develop a lupus-like syndrome, which usually resolves after stopping the medication.

Hepatitis B Reactivation

In patients who are carriers of the hepatitis B virus, the virus may become active again while taking Cimzia. This can lead to liver failure or death. Healthcare providers monitor carriers closely during and after treatment.

Vaccinations

Live vaccines should not be administered while using Cimzia, as the medication suppresses the immune system's ability to respond safely to these vaccines.

Hypersensitivity

Serious allergic reactions, including anaphylaxis, have been reported. If a serious reaction occurs, treatment is typically discontinued immediately.

Pregnancy

Data from clinical studies and pregnancy registries suggest that Cimzia does not increase the risk of major birth defects, miscarriage, or adverse outcomes for the mother or the baby. Unlike many other medications in its class, Cimzia lacks a specific component called the Fc region, which is typically required for a drug to cross the placenta in significant amounts. As a result, there is minimal to no transfer of the medication from the mother to the fetus.

If you are pregnant or planning to become pregnant, it is important to discuss your treatment plan with your doctor. Healthcare providers may encourage participation in a pregnancy exposure registry to monitor the health of both the mother and the baby during and after pregnancy.

Breastfeeding

Cimzia is excreted into human breast milk, but the levels are very low. Because the medication is a large protein molecule, it is likely broken down in the infant's digestive tract, meaning very little of the drug is expected to be absorbed by a breastfeeding child. Research has not shown an increased risk of side effects in infants exposed to the drug through breast milk.

The decision to breastfeed while taking Cimzia should be made in consultation with a healthcare provider, weighing the developmental and health benefits of breastfeeding against the mother's clinical need for the medication.

Available Forms

Cimzia is administered as an injection under the skin (subcutaneous injection). It is supplied in the following formats:

• Prefilled Syringe: A single-dose, disposable syringe containing a liquid solution. This form is designed for ease of use and may be used for self-injection after proper training.
• Lyophilized Powder: A single-dose vial containing a concentrated powder. This form must be reconstituted (mixed) with sterile water by a healthcare professional before it can be injected.

Both forms are intended for single use only. Any unused portion remaining in the vial or syringe should be discarded according to medical guidelines.

FDA Approval and Indications

Cimzia was first approved by the U.S. Food and Drug Administration (FDA) in April 2008. It is classified as a tumor necrosis factor (TNF) blocker. The FDA has approved Cimzia for the treatment of the following conditions in adults:

• Crohn's disease (for reducing signs and symptoms and maintaining clinical response in patients with moderate to severe disease)
• Moderate to severe rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis
• Non-radiographic axial spondyloarthritis with objective signs of inflammation
• Moderate to severe plaque psoriasis

Boxed Warning

The FDA requires a boxed warning for Cimzia due to the following serious safety risks:

• Serious Infections: Patients treated with Cimzia are at increased risk for developing serious infections that may lead to hospitalization or death. These include tuberculosis (TB), bacterial sepsis, and invasive fungal infections (such as histoplasmosis). Patients should be tested for latent TB before starting treatment and monitored for active TB during therapy.
• Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers. While Cimzia is not approved for use in pediatric patients, this risk is noted for the drug class. Cases of non-melanoma skin cancer and Hodgkin's lymphoma have also been reported in adults using these medications.

Regulatory Requirements

Cimzia is available only by prescription. While it does not currently require a Risk Evaluation and Mitigation Strategy (REMS) program, the FDA requires that a Medication Guide be provided to every patient to explain the potential risks and benefits associated with the treatment.

Insurance and Coverage

The out-of-pocket cost for Cimzia is largely determined by your health insurance plan. As a biologic medication, it is often placed in a higher cost-sharing tier on insurance formularies. Your expenses may include copayments, coinsurance, or meeting a deductible before coverage begins.

Specialty Pharmacy Requirements

Cimzia is typically dispensed through a specialty pharmacy rather than a standard retail pharmacy. Specialty pharmacies are equipped to handle high-cost medications that require specific storage conditions, such as refrigeration. These pharmacies often work directly with insurance providers to coordinate coverage and delivery.

Financial Assistance Options

There are several programs that may help reduce the cost of Cimzia for eligible patients:

• Copay Savings Cards: These may be available for individuals with commercial insurance to help lower monthly out-of-pocket expenses.
• Patient Assistance Programs: These programs may provide the medication at a reduced cost or for free to individuals who meet certain income requirements and lack adequate insurance coverage.

For those with Medicare, coverage depends on how the drug is administered. If it is injected by a healthcare professional in a clinic, it may be covered under Medicare Part B. If it is self-injected at home, it is typically covered under a Medicare Part D prescription drug plan.